An observational study in Coronary Artery Disease, CABG and Antiplatelet Therapy of Coronary Artery Bypass, sponsored by Ruijin Hospital. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Ruijin Hospital · Observational
The goal of this observational study is to learn about the very long-term effects of different antiplatelet strategies in patients who underwent coronary artery bypass grafting (CABG) and participated in the original DACAB trial. The main questions it aims to answer are:
Does one year of treatment with ticagrelor plus aspirin (dual antiplatelet therapy) after CABG reduce the risk of major adverse cardiovascular events (MACE) over 10 years compared with aspirin alone or ticagrelor alone?
What are the long-term safety outcomes, including major bleeding events, among patients who received different antiplatelet strategies?
Researchers will compare the three originally randomized groups (ticagrelor plus aspirin, ticagrelor alone, and aspirin alone) to see if a one-year course of dual antiplatelet therapy provides a sustained clinical benefit over a decade.
Participants will:
Be contacted by telephone by the central study team for a one-time follow-up interview.
Provide information about their current health status, any cardiovascular events (such as heart attack, stroke, or repeat revascularization procedures) that have occurred since the last follow-up.
Report their current use of medications, including antiplatelet and other cardiovascular drugs.
Allow researchers to request relevant medical records to verify any reported clinical events.
5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.
This study's enrollment of 500 is above the median of 336 across 1,947 observational studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Ruijin Hospital is the lead sponsor of 635 studies on the registry; 360 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All 500 patients who were enrolled and randomized in the DACAB trial (NCT02201771) between July 2014 and November 2015. These patients underwent elective isolated coronary artery bypass grafting (CABG) with saphenous vein grafting at six tertiary hospitals in China.
For this 10-year extended follow-up study, all original DACAB participants are eligible, regardless of their vital status or medication use during the follow-up period. Information on deceased participants will be collected from medical records, family members, or the national China Centre for Disease Control database to minimize loss to follow-up bias.
Original enrollment and randomization in the DACAB trial
Exclusion Criteria:
Who explicitly refuse to provide informed consent for the 10-year follow-up
Patients originally randomized to receive ticagrelor 90 mg twice daily plus aspirin 100 mg once daily for one year after CABG in the DACAB trial
Patients originally randomized to receive ticagrelor 90 mg twice daily for one year after CABG in the DACAB trial.
Patients originally randomized to receive aspirin 100 mg once daily for one year after CABG in the DACAB trial.
4-Point Major Adverse Cardiovascular Events (4P-MACE)
Time from randomization to the first occurrence of a composite of all-cause death, myocardial infarction, stroke, or coronary revascularization.
Time frame: From randomization to completion of 10-year follow-up
5P-MACE
Time from original randomization to the first occurrence of a composite of all-cause death, myocardial infarction, stroke, coronary repeat revascularization, or other cardiovascular-related rehospitalization.
Time frame: From randomization to completion of 10-year follow-up
3P-MACE
Time from randomization to the first occurrence of a composite of cardiovascular death, myocardial infarction, or stroke.
Time frame: From randomization to 10-year follow-up
All-Cause Death
Time from original randomization to death from any cause.
Time frame: From randomization to 10-year follow-up
Cardiovascular Death
Time from original randomization to death from cardiovascular causes, including death of unknown cause.
Time frame: From randomization to 10-year follow-up
Myocardial Infarction
Time from original randomization to the first occurrence of myocardial infarction.
Time frame: From randomization to 10-year follow-up
Stroke
Time from original randomization to the first occurrence of stroke (including ischemic and hemorrhagic stroke).
Time frame: From randomization to 10-year follow-up
Coronary Repeat Revascularization
Time from original randomization to the first occurrence of any post-procedural PCI or repeat CABG
Time frame: From randomization to 10-year follow-up
Other Cardiovascular-Related Rehospitalization
Time from original randomization to the first occurrence of hospitalization due to other cardiovascular causes besides those included in 4P-MACE, such as unstable angina, heart failure, arrhythmia, aortic syndrome, or peripheral vascular disease.
Time frame: From randomization to 10-year follow-up
Plan to share: Undecided
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ruijin Hospital